# New Jersey — State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

For New Jersey, new drug wac threshold is $670 per WAC unit; price increase % trigger is more than 10% during any 12-month period; generic/biosimilar trigger is generic drug priced at $10 or more by more than 10% during any 12-month period; statute is NJ S.B. 1615, recorded from its source on 2026-08-14.

- **State:** New Jersey
- **New drug WAC threshold:** $670 per WAC unit _(verified: appears in the quote below)_
- **Price increase % trigger:** more than 10% during any 12-month period _(verified: appears in the quote below)_
- **Generic/biosimilar trigger:** generic drug priced at $10 or more by more than 10% during any 12-month period _(verified: appears in the quote below)_
- **Statute:** NJ S.B. 1615 _(verified: appears in the quote below)_

## What the source says

> NJ S.B. 1615 requires manufactures to report certain data points (e.g., NDC, sales volume, manufacturer costs, reasons for WAC increase) if it is increasing the WAC of a brand-name drug by more than 10% or increasing the WAC of a generic drug priced at $10 or more by more than 10% during any 12-month period. Additionally, the state requires reporting if a new drug has a WAC of $670 per WAC unit or more or a biosimilar has a WAC that is not at least 15% less than the WAC of a referenced brand biologic.

## Source

- https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws

Last verified: 2026-08-14. Review by: 2027-02-10.
Part of [State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers](https://referencesource.org/drug-price-transparency-thresholds/).